Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• MDM2 and MDMX proteins inhibit the tumor suppressor p53, a critical mechanism in nearly 50% of human cancers.
• Overexpression of MDM2/MDMX leads to p53 inactivation, promoting cancer development.
• Targeting p53-MDM2/MDMX interactions is a promising strategy for cancer therapy.

Purpose of the Study:

• To identify novel peptide inhibitors of MDM2 and MDMX.
• To characterize the inhibitory potential and binding mechanisms of identified peptides.
• To provide a basis for the rational design of small molecule inhibitors targeting MDMX.

Main Methods:

• Phage display was used to identify an initial peptide inhibitor (pDI).
• Co-crystal structures informed the design of derivative peptides.
• In vitro assays and structural studies were performed to evaluate peptide potency and binding.

Main Results:

• A 12-residue peptide (pDI) with inhibitory activity against MDM2 and MDMX was identified.
• A derivative peptide, pDIQ, demonstrated a 5-fold increase in potency (MDM2 IC50 = 8 nM, MDMX IC50 = 110 nM).
• Structural analysis revealed pDIQ's unique binding features, including conformational changes to access an MDMX-specific hydrophobic site.

Conclusions:

• Peptide pDIQ effectively inhibits MDM2 and MDMX interactions.
• The structural insights into pDIQ binding provide a foundation for designing potent MDMX-specific inhibitors.
• These findings suggest new therapeutic strategies for cancers with p53 pathway dysfunction.